(PRWEB) June 09, 2015
Maine Biotechnology Services, a premier provider of antibody based services is celebrating its 25th year in business. In 1990, Dr. Joseph Chandler founded MBS with the intent to be true partners to life science researchers in their pursuit of ideal antibodies for any application. Over the course of 25 years, MBS has delivered on that promise, adding broad and deep technical expertise in antibody and assay related technologies. MBS serves customers in a dynamic marketplace where timely assay performance is paramount to pharmaceutical and diagnostic development. Continual investment into tools, protocols, and process development have kept MBS at the forefront of the antibody service industry. There is no substitute for longevity and accumulation of complex project experience. While the offering of services and products at MBS has grown considerably, the core commitment to thoughtful, quality antibody development remains the same. MBS remains wholly owned and operated in Portland, Maine, USA.
The cornerstone of antibody and assay development at MBS is a technical team approach to project design and planning. The MBS antibody development strategy focuses on the timely generation of data from large fusion screens that allow for the identification of quality antibody candidates. A rigorous set of innovative and thorough screening tools are creatively developed and executed to meet customer goals with data-driven decision making. If the goals of a project change during the course of development, MBS uses accumulated data to efficiently shift focus to meet the new goals.
To celebrate 25 years of antibody expertise, Maine Biotechnology Services is introducing a new website that fully highlights the value-added services that put MBS among the most trusted antibody and assay service providers. Browse http://www.mainebiotechnology.com and consider the advantage of using MBS for total antibody project management.